05-3710
2-Chlorophenol
SAJ first grade, ≥99.0%
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
ClC6H4OH
CAS Number:
Molecular Weight:
128.56
EC Number:
202-433-2
UNSPSC Code:
12352104
PubChem Substance ID:
Beilstein/REAXYS Number:
1905114
MDL number:
grade
SAJ first grade
assay
≥99.0%
availability
available only in Japan
refractive index
n20/D 1.558 (lit.)
bp
175-176 °C (lit.)
mp
8 °C (lit.)
density
1.241 g/mL at 25 °C (lit.)
SMILES string
Oc1ccccc1Cl
InChI
1S/C6H5ClO/c7-5-3-1-2-4-6(5)8/h1-4,8H
InChI key
ISPYQTSUDJAMAB-UHFFFAOYSA-N
Still not finding the right product?
Explore all of our products under 2-Chlorophenol
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Corr. 1B
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 2
flash_point_f
147.2 °F - closed cup
flash_point_c
64.0 °C - closed cup
ppe
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Chengyang Wu et al.
Water research, 188, 116465-116465 (2020-10-14)
We created a hydrogen-based membrane palladium-film reactor (MPfR) by depositing palladium nanoparticles (PdNPs) on hollow-fiber membranes via autocatalytic hydrogenation to form a Pd-film. The MPfR was used for hydrodechlorination (HDC) of 2,4-dichlorophenol (2,4-DCP). HDC performances and mechanisms were systematically evaluated
Thi Thu Nga Nguyen et al.
The Journal of antimicrobial chemotherapy, 70(3), 731-738 (2014-10-23)
HIV resistance to the integrase inhibitor raltegravir in treated patients is characterized by distinct resistance pathways. We hypothesize that differences in the in vivo dynamics of HIV resistance to raltegravir are due to the genetic context of the integrase present
Julio Alonso-Padilla et al.
PLoS neglected tropical diseases, 8(12), e3259-e3259 (2014-12-05)
The discovery of new therapeutic options against Trypanosoma cruzi, the causative agent of Chagas disease, stands as a fundamental need. Currently, there are only two drugs available to treat this neglected disease, which represents a major public health problem in